Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
Absent, adhere, Antonacci, autoimmune, baricitinib, baseline, born, CETP, cholesteryl, clarified, clarity, cliff, compliance, device, disclaim, dose, easing, EMA, employed, ester, Evacetrapib, exercised, EXPEDITION, expressly, Fed, full, functional, hemoglobin, historic, IIb, Incyte, inflammatory, JAK, Jimmy, labor, lack, Mechanism, mg, mild, Monetary, panel, platform, pooled, prepayment, pro, prove, publicly, quantitative, Quebec, rata, reinforce, release, reliance, secondary, sitagliptin, speak, stage, struggling, successfully, survival, Tennessee, tiered, undue, unemployment, unexpected, Union, uptake, vascular, Western, Whyte
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10 2002 Lilly Stock Plan As Amended Through August 28, 2012
- 11 Statement Re: Computation of Earnings Per Share
- 12 Statement Re: Computation of Ratio of Earnings (Loss) to Fixed Charges
- 31.1 Rule 13A-14(A) Certification of John C. Lechleiter, Chairman, President, and Chief Executive Officer
- 31.2 Rule 13A-14(A) Certification of Derica W. Rice, Executive Vice President, Global Services, and Chief Financial Officer
- 32 Section 1350 Certification
Related press release
LLY similar filings
Filing view
External links
EXHIBIT 11. Statement Re: Computation of Earnings Per Share
(Unaudited)
ELI LILLY AND COMPANY AND SUBSIDIARIES
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2012 | 2011 | 2012 | 2011 | |||||||||||||
(Dollars and shares in millions, except per-share data) | ||||||||||||||||
BASIC | ||||||||||||||||
Net income | $ | 1,326.6 | $ | 1,236.3 | $ | 3,261.3 | $ | 3,489.5 | ||||||||
Average number of common shares outstanding | 1,110.4 | 1,107.3 | 1,110.3 | 1,106.9 | ||||||||||||
Contingently issuable shares | 9.2 | 6.5 | 8.1 | 6.4 | ||||||||||||
Adjusted average shares | 1,119.6 | 1,113.8 | 1,118.4 | 1,113.3 | ||||||||||||
Basic earnings per share | $ | 1.18 | $ | 1.11 | $ | 2.92 | $ | 3.13 | ||||||||
DILUTED | ||||||||||||||||
Net income | $ | 1,326.6 | $ | 1,236.3 | $ | 3,261.3 | $ | 3,489.5 | ||||||||
Average number of common shares outstanding | 1,110.4 | 1,107.3 | 1,110.3 | 1,106.9 | ||||||||||||
Incremental shares – stock options and contingently issuable shares | 9.2 | 6.5 | 8.1 | 6.4 | ||||||||||||
Adjusted average shares | 1,119.6 | 1,113.8 | 1,118.4 | 1,113.3 | ||||||||||||
Diluted earnings per share | $ | 1.18 | $ | 1.11 | $ | 2.92 | $ | 3.13 |